Previous 10 | Next 10 |
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced upcoming participati...
FSD Pharma releases new corporate video providing insight on the Company’s innovation to help millions of people suffering from Multiple Sclerosis Morningstar releases research coverage on HUGE, noting outperformance of peers in recent months and undervalued quantitative valuation ...
FSD Pharma ( NASDAQ: HUGE ) has announced that the company has received confirmation from The Nasdaq that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule. On Feb. 14, 2023, Staff notified the company that for the last ...
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“ FSD Pharma ” or the “ Company ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory...
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced the launch of a new ...
FSD Pharma ( NASDAQ: HUGE ) said it launched of a new research and development program focused on alcohol misuse. "FSD Pharma’s existing pipelines and research priorities in brain and inflammatory disorders, including mental health, provides a natural extension to investigate t...
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“ FSD Pharma ” or the “ Company ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory...
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has received a No Objection Letter from Health Can...
VANCOUVER, British Columbia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabol...
The shares of Canadian biotech FSD Pharma ( NASDAQ: HUGE ) rose for the fourth consecutive session on Tuesday after announcing that Canada greenlighted its Phase 1 trial for multiple sclerosis candidate LUCID-21-302. Issuing a No Objection Letter (NOL), Health Canada has granted the r...
News, Short Squeeze, Breakout and More Instantly...
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has been featured in a news report published by 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of finan...
Denver, Colorado--(Newsfile Corp. - July 25, 2024) - 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial market news and information, today publishes a news report highlighting functional beverage market developments, featuring FSD Pharma (NASDAQ: HUGE...
2024-07-25 08:16:52 ET DENVER, Colo., Jul 25, 2024 ( 247marketnews.com )- Coca-Cola (NYSE: KO ) , FSD Pharma (NASDAQ: HUGE ), and Celsius Holdings, Inc. (NASDAQ: CELH ) Sometimes, there are some winning streaks that are so strong that even...